Abstract CT303: A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors

Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Fadlo R. Khuri(American University of Beirut Medical Center), Meredith Renfroe(Emory University), Bradley Curtis Carthon(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), R. Donald Harvey(Emory University), John Kauh(Houston Methodist Sugar Land Hospital), Colleen Lewis(Emory University), Bassel F. El‐Rayes(University of Alabama at Birmingham), Rijalda Deović(Emory University), Suresh S. Ramalingam(Emory University), Wayne Harris(Emory University), Gabriel Sica(Emory University)

Cancer Research

August 1, 2015

Cited by 0

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2016|3.3k

|The Lancet|2020|1.8k

|New England Journal of Medicine|2021|1.8k

|Nature Immunology|2001|1k

Related Papers